Pulmonx (LUNG) Long-Term Deferred Tax (2019 - 2020)

Pulmonx's (LUNG) quarterly Long-Term Deferred Tax came in at $1.7 million in Q3 2020, up 5.0% on a QoQ basis from $1.6 million in Q4 2019.

Pulmonx (LUNG) Long-Term Deferred Tax (2019 - 2020) Analysis & Trends

Pulmonx (LUNG) has 2 years of Long-Term Deferred Tax data on file, last reported at $1.7 million in Q3 2020.

On a quarterly basis, Long-Term Deferred Tax changed N/A year-over-year to $1.7 million in Q3 2020; TTM through Sep 2020 was $1.7 million, a N/A change from a year earlier, with the FY2019 full-year figure at $1.6 million, changed N/A from the prior year.
Long-Term Deferred Tax for Q3 2020 stood at $1.7 million, up from $1.6 million in the prior quarter.
Over the last five years, Long-Term Deferred Tax for LUNG reached as high as $1.7 million in Q3 2020 and fell as low as $1.6 million in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-
10	Pulmonx	49.94 Mn	-19.81 Mn	-

Download Data

Date	Value
Sep 30, 2020	1.68 Mn
Dec 31, 2019	1.60 Mn